RESUMO
In addition to generalised of bone loss and a higher fracture risk, rheumatoid arthritis (RA) causes periarticular bone erosions. Improvements in bone density/erosion and turnover may not go hand in hand with a positive clinical response to biological anti-inflammatory drugs assesed by disease activity score 28 (DAS28) in RA patients. This study aimed to understand how biologic anti-inflammatory drugs affect bone density, erosion, and turnover in RA patients. We examined bone mineral density (BMD) and bone turnover biomarkers. The study population consisted of 62 RA patients, 49 (79%) of whom were female and 13 (21%) of whom were male. The patients ranged in age from 40 to 79 years old. The patients' BMD was measured using a DEXA scan, and their plasma levels of bone turnover biomarkers CTX and osteocalcin were quantified utilizing an ELISA. BMD of the hip and lumbar spine in responder patients rose after therapy by 0.001g/cm2 (0.11 percent, p0.001 vs. before treatment) and 0.0396g/cm2 (3.96 percent, p0.001 vs. before treatment), respectively. Clinically non-responder patients' DAS28 revealed minor reductions in hip BMD values of -0.008g/cm2 (-0.78 percent, p0.001 vs. before therapy), as well as an improvement in lumbar spine BMD of 0.03g/cm2 (3.03 percent, p0.001 vs. before treatment). After 12 weeks of therapy, the CTX levels in responder patients dropped from 164 125 pg/ml to 131 129 pg/ml. Osteocalcin levels in non-responder patients increased substantially from 11.6 ng/ml to 14.9 ng/ml after 12 weeks of therapy compared to baseline (p = 0.01). Treatment with biologic anti-inflammatory medicines decreases widespread bone loss in RA patients' hip and lumbar spine. The beneficial effects of therapy on BMD were not associated with changes in disease activity of RA patients. Changes in plasma levels of bone turnover biomarkers such as sCTX and osteocalcin confirmed the treatment's beneficial effects.
Assuntos
Absorciometria de Fóton , Artrite Reumatoide , Biomarcadores , Densidade Óssea , Remodelação Óssea , Humanos , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/sangue , Artrite Reumatoide/complicações , Densidade Óssea/efeitos dos fármacos , Feminino , Masculino , Pessoa de Meia-Idade , Biomarcadores/sangue , Idoso , Adulto , Remodelação Óssea/efeitos dos fármacos , Osteocalcina/sangue , Peptídeos/sangue , Colágeno Tipo I/sangueRESUMO
BACKGROUND: Using cardiovascular magnetic resonance imaging (CMR), it is possible to detect diffuse fibrosis of the left ventricle (LV) in patients with atrial fibrillation (AF), which may be independently associated with recurrence of AF after ablation. By conducting CMR, clinical, electrophysiology and biomarker assessment we planned to investigate LV myocardial fibrosis in patients undergoing AF ablation. METHODS: LV fibrosis was assessed by T1 mapping in 31 patients undergoing percutaneous ablation for AF. Galectin-3, coronary sinus type I collagen C terminal telopeptide (ICTP), and type III procollagen N terminal peptide were measured with ELISA. Comparison was made between groups above and below the median for LV extracellular volume fraction (ECV), followed by regression analysis. RESULTS: On linear regression analysis LV ECV had significant associations with invasive left atrial pressure (Beta 0.49, P = 0.008) and coronary sinus ICTP (Beta 0.75, P < 0.001), which remained significant on multivariable regression. CONCLUSION: LV fibrosis in patients with AF is associated with left atrial pressure and invasively measured levels of ICTP turnover biomarker.
Assuntos
Fibrilação Atrial/diagnóstico por imagem , Ventrículos do Coração/diagnóstico por imagem , Imagem Cinética por Ressonância Magnética , Função Ventricular Esquerda , Remodelação Ventricular , Adulto , Idoso , Fibrilação Atrial/sangue , Fibrilação Atrial/fisiopatologia , Fibrilação Atrial/cirurgia , Função do Átrio Esquerdo , Pressão Atrial , Biomarcadores/sangue , Proteínas Sanguíneas , Ablação por Cateter , Colágeno Tipo I/sangue , Técnicas Eletrofisiológicas Cardíacas , Feminino , Fibrose , Galectina 3/sangue , Galectinas , Ventrículos do Coração/metabolismo , Ventrículos do Coração/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Valor Preditivo dos Testes , Pró-Colágeno/sangueRESUMO
Pharmacodynamics (PD) similarity is an important component to support the claim of similarity between two drugs or devices. This article investigates the trial design and statistical considerations in the equivalence test of PD endpoints. Using bone resorption marker CTX as a case study, the relationship between the PD readouts and drug potency was explored to evaluate the sensitivity of the PD endpoint and guide equivalence margin selection. For PD data that have high baseline variability, one conventional similarity assessment method was to apply baseline-normalization followed by the standard bioequivalence (BE) test (Lancet Haematol. 4:e350-61, 2017, Ann Rheum Dis. 2017). This study showcased the drawbacks of the conventional method for PD data that were close to inhibition saturation, as the baseline-normalization significantly skewed the distribution of the PD data toward non-log-normal. In such cases, the standard BE test can produce an inflated type I error. Alternatively, ANCOVA, when applied to the un-normalized PD data with the baseline as a covariate, produced a satisfactory type I error with sufficient power. Therefore, ANCOVA was recommended for equivalence test of PD markers that has a saturated inhibition profile and high variability at baseline. Moreover, the relationship between PD readouts and drug potency was used to explore the sensitivity of the PD endpoint and it could help justify the equivalence margins, since the standard 80% to 125% BE margin often does not apply to PD. Finally, a decision tree was proposed to help guide the design of the PD equivalence study in the choice of PD endpoints and statistical methods.
Assuntos
Ensaios Clínicos como Assunto , Modelos Biológicos , Projetos de Pesquisa , Equivalência Terapêutica , Análise de Variância , Colágeno Tipo I/sangue , Simulação por Computador , Conjuntos de Dados como Assunto , Árvores de Decisões , Denosumab/farmacologia , Humanos , Osteoporose/sangue , Osteoporose/tratamento farmacológico , Peptídeos/sangue , Análise de RegressãoRESUMO
The bone turnover marker (BTM) measurement in osteoporosis treatment includes evaluation of bone metabolism status or evaluation of bone loss risk level, determination of fracture risk, and evaluation of drug treatment. Currently, by using the BTM, it has become possible to evaluate and select an effective treatment for osteoporosis. The BTM has become widely used as a clinical test item in actual clinical practice. Patients' low adherence to osteoporosis medication regimens increases the risk of vulnerable fractures and affects the cost effectiveness of therapeutics. A joint working group has been established, with International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and International Osteoporosis Foundation (IOF) in a central role. The joint policy document of the joint working group is intended to increase the international application of BTM in clinical medicine, and to eliminate blood type I procollagen-N-propeptide (P1NP) and type I collagen cross-linked C-telopeptide (CTX) in observational research and intervention studies, in order to eliminate the inherent uncertainty of these measurements in clinical use. Current osteoporotic drug treatment has been proven to prevent bone fractures, but poor adherence to dosage regimens is an ongoing problem in clinical practice; various attempts have been made to improve adherence. Low adherence to an osteoporosis medication regimen increases the risk of fracture, and affects cost effectiveness. The BTM is an effective indicator in monitoring reactivity to osteoporosis drug therapy, and can be used to individually evaluate guidelines for treatment continuity and medication. In addition, providing BTM information to patients has reportedly improved their adherence to therapeutics, thereby potentially improving both the outcome and cost-effectiveness of osteoporosis drug therapy.
Assuntos
Remodelação Óssea , Osteoporose/tratamento farmacológico , Osteoporose/metabolismo , Biomarcadores/sangue , Colágeno Tipo I/sangue , Análise Custo-Benefício , Humanos , Osteoporose/diagnóstico , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Pró-Colágeno/sangue , Resultado do TratamentoRESUMO
Bone turnover includes two processes: resorption (removal of old bone) and formation (laying down of new bone). N-terminal propeptide of type I procollagen (PINP) and C-telopeptide of type I collagen (CTX-I) are markers of bone formation and resorption, respectively, that the International Osteoporosis Foundation and the International Federation of Clinical Chemistry recommend for clinical use. Bone turnover markers (BTM) are subject to sources of variability, including feeding (lower resorption) and recent fracture (increased levels of all markers). Controllable patient-related factors should be adapted as much as possible (eg blood collection after an overnight fast) to minimize pre-analytical variability. Uncontrollable factors should be considered in the interpretation of the BTM measurements. BTM do not improve prediction of bone loss or fracture within an individual. In osteoporotic patients, BTM may help to assess the response to anabolic and antiresorptive therapies, to assess compliance to the treatment, or to indicate possible secondary causes of osteoporosis. BTM reflect changes in bone metabolism induced by anti-osteoporotic treatment. Anti-resorptive drugs induce a rapid dose-dependent decrease in bone resorption, whereas bone formation stimulating medications increase the levels of bone formations markers. BTM may be used for monitoring anti-osteoporosis therapy. The expected effect during the anti-resorptive therapy is to decrease the PINP by at least 10 ng/mL and to attain the target level of less than 35 ng/mL. The expected effect during the bone formation-stimulating therapy is to increase the PINP by at least 10 ng/mL and to attain the target level of more than 69 ng/mL.
Assuntos
Doenças Ósseas Metabólicas/diagnóstico , Remodelação Óssea/fisiologia , Animais , Biomarcadores/sangue , Densidade Óssea/fisiologia , Doenças Ósseas Metabólicas/metabolismo , Doenças Ósseas Metabólicas/patologia , Reabsorção Óssea/sangue , Reabsorção Óssea/diagnóstico , Reabsorção Óssea/terapia , Osso e Ossos/metabolismo , Colágeno Tipo I/sangue , Fraturas Ósseas/diagnóstico , Fraturas Ósseas/etiologia , Fraturas Ósseas/terapia , Humanos , Osteoporose/diagnóstico , Osteoporose/tratamento farmacológico , Osteoporose/etiologia , Osteoporose/terapia , Peptídeos/sangueRESUMO
BACKGROUND: In chronic rheumatic mitral regurgitation (CRMR), involvement of the myocardium in the rheumatic process has been controversial. Therefore, we sought to study the presence of fibrosis using late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR) and biomarkers of collagen turnover in CRMR. METHODS: Twenty-two patients with CRMR underwent CMR and echocardiography. Serum concentrations of matrix metalloproteinase- 1 (MMP-1), tissue inhibitor of MMP-1 (TIMP- 1), MMP-1-to-TIMP-1 ratio, procollagen III N-terminal pro-peptide (PIIINP) and procollagen type IC peptide (PIP) were measured. RESULTS: Four patients had fibrosis on LGE-CMR. PICP and PIIINP concentrations were similar to those of the controls, however MMP-1 concentration was increased compared to that of the controls (log MMP-1 3.5 ± 0.7 vs 2.7 ± 0.9, p = 0.02). There was increased MMP-1 activity as the MMP-1-to- TIMP-1 ratio was higher in CRMR patients compared to the controls ( -1.2 ± 0.6 vs -2.1 ± 0.89, p = 0.002). CONCLUSIONS: Myocardial fibrosis was rare in CRMR patients. CRMR is likely a disease characterised by the predominance of collagen degradation rather than increased synthesis and myocardial fibrosis.
Assuntos
Doença Crônica , Colágeno/sangue , Meios de Contraste/administração & dosagem , Gadolínio DTPA/administração & dosagem , Imageamento por Ressonância Magnética , Insuficiência da Valva Mitral , Miocárdio , Cardiopatia Reumática , Adulto , Biomarcadores/sangue , Colágeno Tipo I/sangue , Estudos Transversais , Feminino , Fibrose , Humanos , Masculino , Metaloproteinase 1 da Matriz/sangue , Pessoa de Meia-Idade , Insuficiência da Valva Mitral/sangue , Insuficiência da Valva Mitral/diagnóstico por imagem , Insuficiência da Valva Mitral/patologia , Insuficiência da Valva Mitral/fisiopatologia , Miocárdio/metabolismo , Miocárdio/patologia , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Valor Preditivo dos Testes , Pró-Colágeno/sangue , Estudos Prospectivos , Cardiopatia Reumática/sangue , Cardiopatia Reumática/diagnóstico por imagem , Cardiopatia Reumática/patologia , Cardiopatia Reumática/fisiopatologia , Inibidor Tecidual de Metaloproteinase-1/sangue , Função Ventricular Esquerda , Remodelação Ventricular , Adulto JovemAssuntos
Biomarcadores/sangue , Remodelação Óssea , Imunoensaio/normas , Osteoporose/diagnóstico , Colágeno Tipo I/sangue , Colágeno Tipo I/normas , Humanos , Laboratórios Hospitalares/normas , Fragmentos de Peptídeos/sangue , Fragmentos de Peptídeos/normas , Peptídeos/sangue , Peptídeos/normas , Pró-Colágeno/sangue , Pró-Colágeno/normas , Valores de ReferênciaRESUMO
Objective There is scant research examining the prevalence of thinness in early childhood, despite its potential negative consequences for health and development across the life course. The objective of this study was to assess bone status through measurement of bone mineral density and biochemical bone turnover markers, with special attention paid to carboxylated (c-OC) as well as undercarboxylated (uc-OC) forms of osteocalcin, in the groups of thin and normal-weight children. Design The study included 80 healthy prepubertal children (median age 7.0 years), who were divided (according to Cole's international cutoffs) into 2 subgroups: thin children ( n = 40, body mass index [BMI] = 13.5 kg/m2) and normal-weight children ( n = 40, BMI = 16.1 kg/m2). Bone mineral density (BMD) and bone mineral content (BMC) were assessed by dual-energy x-ray absorptiometry method. Serum concentrations of C-terminal telopeptide of collagen type I (CTX), total osteocalcin (OC), and c-OC, and uc-OC forms of osteocalcin were determined using enzyme-linked immunosorbent assays. Results In thin children, we observed higher levels of bone resorption marker CTX compared with normal-weight peers. Total osteocalcin concentrations were comparable in both groups of children; however, in thin children we observed higher median values of uc-OC (34.40 vs. 29.30 ng/mL, P < 0.05) and similar c-OC levels (25.65 vs. 28.80 ng/mL). The ratio of c-OC to uc-OC was significantly lower ( P < 0.05) in thin than in normal-weight children. Total BMD and BMC were significantly decreased ( P < 0.0001) in thin children compared with normal-weight peers (0.724 ± 0.092 vs. 0.815 ± 0.060 g/cm2 and 602.7 ± 159.2 vs. 818.2 ± 220.1 g, respectively). Conclusion Increased concentrations of CTX and uc-OC might lead to disturbances in bone turnover and a decrease in bone mineral density in thin children.
Assuntos
Biomarcadores/sangue , Densidade Óssea/fisiologia , Remodelação Óssea/fisiologia , Osteocalcina/sangue , Absorciometria de Fóton/métodos , Antropometria/métodos , Índice de Massa Corporal , Desenvolvimento Ósseo/fisiologia , Reabsorção Óssea/metabolismo , Osso e Ossos/diagnóstico por imagem , Osso e Ossos/metabolismo , Criança , Pré-Escolar , Colágeno Tipo I/sangue , Feminino , Humanos , Masculino , Polônia/epidemiologia , MagrezaRESUMO
BACKGROUND: Despite the benefits related to the use of bisphosphonates and denosumab, medication-related osteonecrosis of the jaw (MRONJ) is a serious complication. The purpose of this study was to investigate the utility of 4 biochemical markers including serum c-terminal telopeptide cross-link of type I collagen (s-CTX), serum osteocalcin (s-OC), serum parathormon (s-PTH), and serum bone-specific alkaline phosphatase (s-BAP) as useful clinical tools to help assess the risk for MRONJ prior to invasive oral surgery. MATERIALS AND METHODS: Twenty patients diagnosed with MRONJ and 20 controls who have been on antiresorptive therapies with no occurrence of MRONJ were included in this 2-arm cross-sectional study. The s-CTX, s-OC, s-PTH, and s-BAP values were measured. Mann-Whitney U test compared the s-CTX, s-OC, s-PTH, and s-BAP values of the MRONJ group and the controls (Pâ<â0.05). RESULTS: Lower values were observed in the MRONJ group compared with the control group for s-CTX (130.00âpg/mL versus 230.0âpg/mL; Pâ=â0.12) and for s-OC (10.6âng/mL versus 14.80âng/mL; Pâ=â0.051) both without significance and for s-BAP (0.23âµkat/L versus 0.31âµkat/L; Pâ=â0.002) with significance. By contrast, the median s-PTH value of the MRONJ group was higher (30.65âng/L versus 25.50âng/L; Pâ=â0.89), but without significance. CONCLUSIONS: The evaluation of the 4 biochemical markers showed that only the value of s-BAP was significantly decreased in the MRONJ patients compared with the controls. Presently, because of the lack of evidence, a routine check prior to oral surgery for the risk assessment of MRONJ cannot be recommended.
Assuntos
Fosfatase Alcalina/sangue , Osteonecrose da Arcada Osseodentária Associada a Difosfonatos/sangue , Remodelação Óssea , Colágeno Tipo I/sangue , Osteocalcina/sangue , Hormônio Paratireóideo/sangue , Peptídeos/sangue , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Conservadores da Densidade Óssea/efeitos adversos , Estudos Transversais , Denosumab/efeitos adversos , Difosfonatos/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição de RiscoAssuntos
Colágeno Tipo I/sangue , Testes Diagnósticos de Rotina/classificação , Testes Diagnósticos de Rotina/economia , Peptídeos/sangue , Mecanismo de Reembolso , Terminologia como Assunto , Biomarcadores/sangue , Análise Química do Sangue/classificação , Análise Química do Sangue/economia , Análise Química do Sangue/normas , Reabsorção Óssea/sangue , Reabsorção Óssea/diagnóstico , Colágeno Tipo I/análise , Testes Diagnósticos de Rotina/normas , França , Humanos , Peptídeos/análise , Padrões de Referência , Mecanismo de Reembolso/classificaçãoRESUMO
CONTEXT: Bone gain vs loss across the skeleton loss depends on the balance between total bone formation and total bone resorption. OBJECTIVE: The objective of the study was to determine whether resorption and formation markers can be combined to gauge net bone formation across the skeleton. DESIGN: The study included a cohort followed up across menopause transition (Study of Women's Health Across the Nation). SETTING AND PARTICIPANTS: Community-dwelling women, 42-52 years old, premenopausal or early perimenopausal at baseline, participated in the study. OUTCOME: The study included the following measures: 1) bone balance index (BBI) created by estimating the relationship between resorption (urinary N-telopeptide) and formation (osteocalcin) markers when the total formation equals the total resorption in 685 women with stable bone mineral density (BMD) (>5 y before the final menstrual period [FMP]) and applying this relationship to measured bone turnover markers in 216 women beginning to lose bone (≤2 y from FMP); and 2) annualized percentage declines over the following 3-4 years in the lumbar spine (LS) and femoral neck (FN) BMD. RESULTS: Adjusted for covariates, the BBI was greater (more favorable) in women with a greater body mass index (P = .03) and lower (less favorable) in women closer to the FMP (P = .007). Each SD decrement in BBI was associated with 0.27%/y faster LS BMD decline (P 0.04) and a 38% higher odds of faster-than-average loss of LS bone mass (P = .008, c-statistic 0.76). BBI was not associated with decline in FN BMD. Urinary N-telopeptide alone was not associated with either LS or FN BMD decline. CONCLUSIONS: An index that quantifies net bone formation vs resorption can be created from bone turnover markers and may help identify individuals at high risk for LS bone loss.
Assuntos
Densidade Óssea , Reabsorção Óssea/metabolismo , Indicadores Básicos de Saúde , Osteogênese/fisiologia , Adulto , Biomarcadores/metabolismo , Remodelação Óssea/fisiologia , Colágeno Tipo I/sangue , Feminino , Seguimentos , Homeostase , Humanos , Estudos Longitudinais , Menopausa/metabolismo , Pessoa de Meia-Idade , Osteocalcina/sangue , Osteoporose Pós-Menopausa/diagnóstico , Osteoporose Pós-Menopausa/metabolismo , Peptídeos/sangueRESUMO
BACKGROUND/OBJECTIVES: Primary adult-type lactose malabsorption (PALM) is a widespread inherited autosomal recessive condition, which is considered to be associated with osteoporosis. This prospective study aimed at assessing the 25-hydroxy-vitamin D (25(OH)D) status and serum CrossLaps levels in individuals with PALM and normal controls. SUBJECTS/METHODS: All participants (n=210) underwent genotyping for the LCT C/T-13910 polymorphism, 25(OH)D and CrossLaps measurements and clinical examinations. In addition, the anthropometric data (that is, height, weight and body mass index) were determined. RESULTS: Fifty-five individuals with PALM (that is, LCT C/C-13910 homozygotes) showed lower 25(OH)D (mean: 24.95±10.04 vs 28.59±9.56 ng/ml, P=0.018) and higher CrossLaps serum levels (mean: 0.46±0.31 vs 0.43±0.49 ng/ml, P=0.251) compared with 155 normal controls (that is, LCT C/T-13910 hetero- or T/T-13910 homozygotes). Anthropometric data were similar between PALM probands and controls. CONCLUSIONS: Individuals with PALM were found to have lower 25(OH)D and higher CrossLaps serum levels compared with normal controls. In order to preserve life-long bone health, routine 25(OH)D and CrossLaps serum measurements should be performed in individuals with PALM.
Assuntos
Colágeno Tipo I/sangue , Colágeno/sangue , Absorção Intestinal , Lactase/deficiência , Intolerância à Lactose/complicações , Lactose/metabolismo , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Deficiência de Vitamina D/complicações , Vitamina D/análogos & derivados , Adulto , Índice de Massa Corporal , Feminino , Genótipo , Humanos , Lactase/sangue , Lactase/genética , Lactase/metabolismo , Intolerância à Lactose/sangue , Intolerância à Lactose/genética , Masculino , Pessoa de Meia-Idade , Osteoporose/etiologia , Osteoporose/genética , Polimorfismo de Nucleotídeo Único , Estudos Prospectivos , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Vitaminas/sangue , Adulto JovemRESUMO
The identification of early biochemical predictors of osteoarthritis (OA) has been the focus of much research over the past few years. However, it still is unclear whether current biochemical markers can be used in prognostic risk assessment of OA. The aim of this systematic review is to evaluate the possible prognostic application of blood and urinary biochemical markers of knee and hip OA. Abstract and full text selection was done by two independent reviewers. A total of 25 relevant publications including 37 biochemical markers of bone and cartilage turnover and inflammation associated with some aspects of OA were reviewed. Most of those biomarkers were studied only once or twice. Due to heterogeneity of both OA-phenotype and determinant among the publications, meta-analysis of the studied biochemical markers was not possible. There was strong evidence for urinary C-terminal telopeptide of collagen type II (uCTX-II) as a prognostic marker for knee OA progression and serum cartilage oligomeric protein (COMP) level as prognostic marker for incidence of knee and hip OA. Evidence for prognostic value of C-reactive protein is still inconclusive. International standardization of future investigations should be pursued to obtain more high-quality, homogenous data on the full spectrum of biochemical OA markers.
Assuntos
Cartilagem Articular/metabolismo , Osteoartrite do Quadril/diagnóstico , Osteoartrite do Joelho/diagnóstico , Biomarcadores/sangue , Biomarcadores/urina , Proteína C-Reativa/metabolismo , Proteína de Matriz Oligomérica de Cartilagem/sangue , Proteína de Matriz Oligomérica de Cartilagem/urina , Colágeno Tipo I/sangue , Colágeno Tipo I/urina , Progressão da Doença , Humanos , Osteoartrite do Quadril/sangue , Osteoartrite do Quadril/urina , Osteoartrite do Joelho/sangue , Osteoartrite do Joelho/urina , Peptídeos/sangue , Peptídeos/urina , Prognóstico , Medição de Risco/métodosRESUMO
OBJECTIVES: Serum tartrate-resistant acid phosphatase 5b (TRACP5b) is a bone resorption marker used in the assessment of bone metabolic status. The present study was designed to determine the clinical characteristics and utility of measuring serum TRACP5b levels in peritoneal dialysis (PD) patients. DESIGN: Cross-sectional study. PATIENTS: Forty-one patients receiving PD treatment in a single centre. MEASUREMENT: Serum levels of the bone turnover markers TRACP5b, N-terminal cross-linking telopeptide of type 1 collagen (NTX), bone-specific alkaline phosphatase (BAP), and parathyroid hormone (PTH) were simultaneously measured. The correlation of serum TRACP5b with other established bone markers was analysed after logarithmic transformation. Multivariate linear regression analysis was performed to examine the effects of both renal and peritoneal Kt/V (an index for solute clearance) for urea on bone markers using age, sex, body mass index, and PTH as covariates. Bone markers were also measured in three patients before and after treatment with cinacalcet hydrochloride, alphacalcidol, and raloxifene hydrochloride. RESULTS: Log TRACP5b was significantly correlated with log NTX, log BAP and log PTH. In the multivariate analysis, peritoneal Kt/V was not correlated with log NTX, log BAP or log TRACP5b. In contrast, renal Kt/V was significantly correlated with log NTX only. Responses to drug treatment were more accurately determined from serum TRACP5b and BAP than from serum NTX. CONCLUSIONS: Serum TRACP5b and BAP are potentially useful biomarkers for the evaluation of bone turnover in PD patients because they correlate well with other established bone markers and they are not influenced by renal and peritoneal clearances.
Assuntos
Fosfatase Ácida/sangue , Reabsorção Óssea/sangue , Isoenzimas/sangue , Diálise Peritoneal/efeitos adversos , Injúria Renal Aguda/tratamento farmacológico , Injúria Renal Aguda/terapia , Adulto , Idoso , Fosfatase Alcalina/sangue , Biomarcadores/sangue , Reabsorção Óssea/diagnóstico , Osso e Ossos/enzimologia , Cinacalcete , Colágeno Tipo I/sangue , Estudos Transversais , Feminino , Humanos , Hidroxicolecalciferóis/uso terapêutico , Masculino , Pessoa de Meia-Idade , Naftalenos/uso terapêutico , Hormônio Paratireóideo/sangue , Peptídeos/sangue , Cloridrato de Raloxifeno/uso terapêutico , Análise de Regressão , Fosfatase Ácida Resistente a TartaratoRESUMO
CONTEXT: In HIV-infected men, the antiresorptive effects of zoledronate persist for at least 2 yr after the second annual dose. OBJECTIVE: Our objective was to determine the duration of action of zoledronate in men. DESIGN AND SETTING: This was 4-yr extension of a 2-yr, double-blind, randomized, placebo-controlled trial at an academic research center. PARTICIPANTS: Participants included 43 HIV-infected men with bone mineral density (BMD) T score below -0.5, 35 of whom entered the extension study. INTERVENTION: Intervention was annual administration of 4 mg iv zoledronate or placebo at baseline and 1 yr and no intervention subsequently. MAIN OUTCOME MEASURES: We evaluated changes in the bone turnover markers, serum osteocalcin and serum C-telopeptide (CTx), and changes in BMD at the lumbar spine, total hip, and total body. RESULTS: There was no time × treatment interaction between 1 and 5 yr after the second zoledronate dose for osteocalcin or CTx (P > 0.4) or any BMD site (P > 0.7). Between 1 and 5 yr after the second dose, on average, osteocalcin was 41% lower (95% confidence interval = 19-62%; P < 0.001), CTx 52% lower (33-71%; P < 0.001), lumbar spine BMD 3.7% greater (0.3-7.0%; P = 0.03), total hip BMD 2.3% greater (0.3-4.3%; P = 0.02), and total body BMD 2.5% greater (0.8-4.1%; P = 0.004) in the zoledronate group than the placebo group. Five years after the second dose, the between-groups differences were 38% (13-62%) for osteocalcin, 49% (20-77%) for CTx, 3.5% (0.7-6.7%) for lumbar spine BMD, 3.4% (1.4-5.4%) for total hip BMD, and 1.6% (0.2-3.1%) for total body BMD. CONCLUSION: The effects of two annual 4-mg doses of zoledronate in men persist for at least 5 yr after the second dose. Larger trials assessing the antifracture efficacy of less frequent dosing of zoledronate are justified.
Assuntos
Terapia Antirretroviral de Alta Atividade , Conservadores da Densidade Óssea/administração & dosagem , Densidade Óssea/efeitos dos fármacos , Remodelação Óssea/efeitos dos fármacos , Difosfonatos/administração & dosagem , Infecções por HIV/tratamento farmacológico , Imidazóis/administração & dosagem , Adulto , Biomarcadores/sangue , Colágeno Tipo I/sangue , Relação Dose-Resposta a Droga , Humanos , Injeções Intravenosas , Masculino , Cadeias de Markov , Pessoa de Meia-Idade , Osteocalcina/sangue , Peptídeos/sangue , Ácido ZoledrônicoRESUMO
OBJECTIVE: Osteoporosis diagnosis is based on bone mineral density (BMD) but bone remodeling is also a crucial issue. It can be assessed by bone turnover markers (BTMs). Their interest for the positive and etiological diagnosis of osteoporosis at baseline, and their predictive value for past asymptomatic vertebral fractures, were evaluated by a systematic review of the literature. METHODS: Medline database was searched to identify all published reports analyzing BTMs and BMD or fractures. We conducted meta-analyses on BTMs levels according to osteoporotic status using random effects models. RESULTS: Moderate and negative correlations were found, mainly in postmenopausal women, between BTMs and BMD, especially with bone alkaline phosphatase (bone ALP), osteocalcin, serum C-terminal and urine N-terminal crosslinking telopeptides of type I collagen (sCTX and uNTX). Bone ALP and sCTX levels are higher in osteoporotic patients compared to controls. High levels of bone ALP in primary hyperparathyroidism and low levels of osteocalcin in endogenous hypercorticism are the most relevant data reported in endocrine diseases associated with osteoporosis. High levels of BTMs, especially osteocalcin, bone ALP or sCTX, may be associated with prevalent vertebral fractures. CONCLUSION: The diagnosis value of BTMs at baseline in osteoporosis is very low. The interest of BTMs for the etiological diagnostic of secondary osteoporosis has not been demonstrated. Data are lacking to address the interest of BTMs assessment to screen for vertebral fractures in asymptomatic patients with high risk factors of fractures.
Assuntos
Remodelação Óssea/fisiologia , Osteoporose/diagnóstico , Fosfatase Alcalina/metabolismo , Biomarcadores/metabolismo , Densidade Óssea , Colágeno Tipo I/sangue , Colágeno Tipo I/urina , Feminino , Humanos , Masculino , Menopausa , Metanálise como Assunto , Osteocalcina/metabolismo , Osteoporose/metabolismo , Fraturas por Osteoporose/diagnóstico , Fraturas por Osteoporose/metabolismo , Peptídeos/sangue , Peptídeos/urina , Valor Preditivo dos TestesRESUMO
UNLABELLED: Among a group of 940 US adults, economic adversity and minority race status were associated with higher serum levels of markers of bone turnover. These results suggest that higher levels of social stress may increase bone turnover. INTRODUCTION: To determine socioeconomic status (SES) and race differences in levels of bone turnover. METHODS: Using data from the Biomarker Substudy of the Midlife in the US (MIDUS) study (491 men, 449 women), we examined cross-sectional associations of SES and race with serum levels of bone turnover markers (bone-specific alkaline phosphatase [BSAP], procollagen type I N-terminal propeptide [PINP], and N-telopeptide [Ntx]) separately in men and women. Linear multivariable regression was used to control for body weight, menopausal transition stage, and age. RESULTS: Among men, low family poverty-to-income ratio (FPIR) was associated with higher turnover, but neither education nor race was associated with turnover. Men with FPIR <3 had 1.808 nM BCE higher Ntx (P = 0.05), 3.366 U/L higher BSAP (P = 0.02), and 7.066 higher PINP (P = 0.02). Among women, neither education nor FPIR was associated with bone turnover, but Black women had 3.688 nM BCE higher Ntx (P = 0.001), 5.267 U/L higher BSAP (P = 0.005), and 11.906 µg/L higher PINP (P = 0.008) compared with non-Black women. CONCLUSIONS: Economic adversity was associated with higher bone turnover in men, and minority race status was associated with higher bone turnover in women, consistent with the hypothesis that higher levels of social stresses cause increased bone turnover. The magnitude of these associations was comparable to the effects of some osteoporosis medications on levels of turnover.
Assuntos
Remodelação Óssea/fisiologia , Reabsorção Óssea/etnologia , Classe Social , Adulto , Negro ou Afro-Americano/psicologia , Idoso , Fosfatase Alcalina/sangue , Biomarcadores/sangue , Remodelação Óssea/genética , Reabsorção Óssea/sangue , Reabsorção Óssea/etiologia , Colágeno Tipo I/sangue , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/sangue , Peptídeos/sangue , Pobreza , Pró-Colágeno/sangue , Caracteres Sexuais , Fatores Socioeconômicos , Estresse Psicológico/sangue , Estresse Psicológico/complicações , Estresse Psicológico/etnologia , Estados Unidos/epidemiologiaRESUMO
PURPOSE: the purpose of this retrospective study was to examine the possibility of utilizing serum C-terminal telopeptide cross-link of type I collagen (s-CTX) and serum osteocalcin (s-OC) as risk markers for oral bisphosphonate-related osteonecrosis of the jaws (BRONJ). PATIENTS AND METHODS: the s-CTX values and the s-OC values were measured from 23 patients (one male, 22 females) diagnosed with BRONJ using clinical and radiographic examinations. The two biochemical markers were evaluated during a regular checkup for osteoporosis management. For the control group of s-CTX study, s-CTX values were obtained from 61 independently recruited postmenopausal women who have been on bisphosphonate therapy for >6 months. The s-CTX values of the ONJ group and the control group were compared. Because of retrospective nature of this study, the control group for s-OC study could not be established. A single sample t-test was performed for the s-OC value from the ONJ group. RESULT: twenty-three ONJ patients had taken alendronate for osteoporosis treatment, and the s-CTX testing results were low levels of 10-192 pg/ml (mean: 93.2 ± 49.4 pg/ml). Mean of s-CTX of the control (n=61) was 125 ± 85.7 pg/ml. The duration of BP therapy ranged between 1 and 10 years (4.82 ± 2.6). The s-OC level was estimated between 0.2 and 5.4 ng/ml (1.91 ± 1.51 ng/ml). The mean s-CTX value of the control group was higher but without significance (P=0.12). The s-OC values of the ONJ group were significantly lower than the lowest value of the reference range (P<0.001). CONCLUSION: as a result of the s-CTX and s-OC testings at the diagnosis of BRONJ, the values of the two markers were decreased. The decrease of the s-OC values implies a problem during the bone-formation process. Therefore, we can assume that in this patient group, invasive dental surgery contributes to an increase in the risk of BRONJ incidence. This result may imply that, during bisphosphonate therapy, simultaneous consideration of s-CTX showing inhibition of bone resorption and s-OC indicating the degree of bone formation might be a set of risk markers assessing risk prediction for BRONJ before invasive dental surgery.
Assuntos
Alendronato/efeitos adversos , Biomarcadores/sangue , Conservadores da Densidade Óssea/efeitos adversos , Doenças Maxilomandibulares/induzido quimicamente , Osteonecrose/induzido quimicamente , Administração Oral , Idoso , Idoso de 80 Anos ou mais , Alendronato/administração & dosagem , Conservadores da Densidade Óssea/administração & dosagem , Colágeno Tipo I/sangue , Contraindicações , Feminino , Humanos , Doenças Maxilomandibulares/sangue , Masculino , Pessoa de Meia-Idade , Osteocalcina/sangue , Osteonecrose/sangue , Osteoporose/prevenção & controle , Peptídeos/sangue , Estudos Retrospectivos , Medição de Risco , Estatísticas não Paramétricas , Cirurgia BucalRESUMO
BACKGROUND: Bone complications after hematopoietic stem-cell transplantation (HSCT) are relatively frequent. Evaluation of biomarkers of bone turnover and dual energy x-ray absorptiometry (DEXA) are not known in this context. METHODS: We prospectively evaluated bone mineral density, biomarkers of bone turnover, and the cumulative incidence of bone complications after allogeneic HSCT. One hundred forty-six patients were included. Bone mineral density was measured by DEXA 2-month and 1-year post-HSCT. The markers of bone turnover were serum C-telopeptide (C-TP), 5 tartrate-resistant acid phosphatase (bone resorption), and osteocalcin (bone formation) determined pre-HSCT and 2 months and 1 year thereafter. Potential association between osteoporosis at 2 months, osteoporotic fracture or avascular necrosis and, individual patient's characteristics and biologic markers were tested. RESULTS: C-TP was high before and 2 months after transplant. At 2 months, DEXA detected osteoporosis in more than half the patients tested. Male sex, median age less than or equal to 15 years, and abnormal C-TP before HSCT were risk factors significantly associated with osteoporosis. Three-year cumulative incidences of fractures and avascular necrosis were 8% and 11%, respectively. Children were at higher risk of fracture, whereas corticosteroid treatment duration was a significant risk factor for developing a clinical bone complication post-HSCT. Bone complications and osteoporosis are frequent after HSCT. Bone biologic markers and DEXA showed that subclinical bone abnormalities appeared early post-HSCT. CONCLUSION: The risk factors, age, gender, and C-TP easily available at the time of transplantation were identified. Biphosphonates should probably be given to patients with those risk factors.
Assuntos
Doenças Ósseas/epidemiologia , Osso e Ossos/metabolismo , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante Homólogo/fisiologia , Adolescente , Adulto , Densidade Óssea , Doenças Ósseas/etiologia , Doenças Ósseas/patologia , Criança , Colágeno Tipo I/sangue , Ciclosporina/uso terapêutico , Feminino , Fraturas Ósseas/epidemiologia , Fraturas Ósseas/etiologia , Humanos , Imunossupressores/uso terapêutico , Incidência , Masculino , Necrose , Peptídeos/sangue , Fatores de Risco , Caracteres Sexuais , Fatores de Tempo , Transplante Homólogo/efeitos adversos , Irradiação Corporal Total/efeitos adversosRESUMO
The "J shape" curve linking the risk of poor bone health to alcohol intake is now well recognized from epidemiological studies. Ethanol and nonethanol components of alcoholic beverages could influence bone remodeling. However, in the absence of a solid underlying mechanism, the positive association between moderate alcoholic intake and BMD remains questionable because of confounding associated social factors. The objective of this work was to characterize the short-term effects of moderate alcohol consumption on circulating bone markers, especially those involved in bone resorption. Two sequential blood-sampling studies were undertaken in fasted healthy volunteers (age, 20-47 yr) over a 6-h period using beer of different alcohol levels (<0.05-4.6%), solutions of ethanol or orthosilicic acid (two major components of beer), and water +/- calcium chloride (positive and negative controls, respectively). Study 1 (24 subjects) assessed the effects of the different solutions, whereas study 2 (26 subjects) focused on ethanol/beer dose. Using all data in a "mixed effect model," we identified the contributions of the individual components of beer, namely ethanol, energy, low-dose calcium, and high-dose orthosilicic acid, on acute bone resorption. Markers of bone formation were unchanged throughout the study for all solutions investigated. In contrast, the bone resorption marker, serum carboxy terminal telopeptide of type I collagen (CTX), was significantly reduced after ingestion of a 0.6 liters of ethanol solution (>2% ethanol; p